If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-24. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
=== Contestants === 1st - Rudy Martinez, Home Bakery Owner from Queens, New York 2nd - Scott Breazeale, Executive Chef from Plymouth, Michigan 3rd - Jason Hisley, Bakery Owner and chef from Baltimore, Maryland 4th - Ashlee Prisbrey, Baker from Salt Lake City, Utah 5th - Audrey Alfaro, Home Baker from Spokane, Washington 6th - Erin Cooper, Baker from Owings Mills, Maryland 7th - Jennifer Petty, Home Bakery Owner from West Covina, California
This is seen with the subcutaneous injection of triptans for migraine headache, medroxyprogesterone acetate for contraception, as well as many monoclonal antibodies. In most cases, injection site reactions are self-limiting and resolve on their own after a short time without treatment, and do not require the medication to be discontinued. The administration of vaccines subcutaneously is also associated with injection site reactions. This includes the BCG vaccine which is associated with a specific scar appearance which can be used as evidence of prior vaccination. Other subcutaneous vaccines, many of which are live vaccines including the MMR vaccine and the varicella vaccine, which may cause fever and rash, as well as a feeling of general malaise for a day or two following the vaccination.
Sam Lonergan (born 26 March 1987) is a former professional Australian rules footballer who played for the Essendon Football Club and Richmond Football Club in the Australian Football League (AFL). He was drafted from the Launceston Football Club, via the Tassie Mariners U18s and the Tasmanian Devils, with selection 50 in the 2005 Draft. Lonergan captained the Allies (a composite team drawn from Tasmania, New South Wales, Queensland, the Australian Capital Territory and the Northern Territory), against Victoria during Grand Final week. In that game, he kicked five goals and was the leading possession winner on the ground. He also became the first player in the history of the Tassie Mariners U18s to win successive best and fairest awards. He also played eight games in 2005 for the Tasmanian Devils Football Club in the VFL competition. Lonergan was chosen as Tasmania's most valuable player at the under-18 championships in 2005, and won the Tassie Mariners U18 Best & Fairest award that same year. He was also chosen in the under-18 All-Australian side. After a 2012 season where he played 14 games and broke the shoulder blade of Andrew Carrazzo; he was delisted by the Essendon Football Club on 30 October 2012. Lonergan was picked up by Richmond in the 2012 Rookie draft, played two games for the club in 2013 and retired at the end of that year. Lonergan also supported Richmond while growing up.
Sources: en.wikipedia.org
=== Development === In July 2018, DC Universe gave a series order to Stargirl, consisting of thirteen episodes. The pilot was written by Geoff Johns, who also executive produces alongside Greg Berlanti, Sarah Schechter, and Melissa Carter (who is co-showrunner with Johns). Production companies involved with the series are Mad Ghost Productions, Berlanti Productions, and Warner Bros. Television. The series was said to be a "reimagining" of Stargirl. The CW renewed the series for a second season in July 2020, resulting in the series moving exclusively to the network as a CW original series. The second season is subtitled Summer School. Ahead of the second-season premiere, The CW renewed the series for a third season in May 2021. The renewal allowed the series to be co-financed by HBO Max, part of a larger deal between The CW and HBO Max. The third season is subtitled Frenemies. The CW canceled the show with the third and last season, ending on December 7, 2022.
=== Draft and minor leagues === The Boston Red Sox selected Bagwell in the fourth round (110th overall) of the 1989 Major League Baseball draft. Throughout his career, Barry Axelrod served as his agent. For his first professional assignment, the Red Sox appointed Bagwell to the Single-A Winter Haven Red Sox of the Florida State League in 1989, where he batted .310 with two home runs. In 1990, while playing for the Double-A New Britain Red Sox, Bagwell won the Eastern League Most Valuable Player Award. In 136 games with New Britain, he batted .333 with 160 hits, four home runs (HR), 61 runs batted in (RBI), 34 doubles, seven triples, 73 bases on balls (BB or walks), 57 strikeouts (SO), .422 on-base percentage (OBP), .457 slugging percentage (SLG) and .880 on-base plus slugging percentage (OPS). He finished first in the league in hits and doubles, second in batting, OBP and OPS, fourth in walks, fifth in SLG, ninth in runs scored and tenth in RBI. Late in the 1990 season, the Red Sox, who were in search of relief pitching to improve their chances of making the playoffs, contacted the Houston Astros about Larry Andersen. Stan Benjamin, who scouted the New England region for the Astros, recommended that they ask for Bagwell in return. The Astros initially hesitated owing to his sparse home run production, but Benjamin persuaded them, quipping that New Britain's Beehive Field was so large that "Babe Ruth couldn't hit home runs in that ballpark."[a] On August 30, 1990, the Red Sox took the Astros' offer.
== Contraindications == Use of verapamil is generally avoided in people with severe left ventricular dysfunction, hypotension (systolic blood pressure less than 90 mm Hg), cardiogenic shock, and hypersensitivity to verapamil. It is also contraindicated in people with atrial flutter or fibrillation and an existing accessory tract such as in Wolff-Parkinson-White syndrome.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.